In Estonia, the development of health technologies has entered a more coordinated phase, which received a significant boost in the autumn of 2025 with the signing of a memorandum of understanding (MOU). The memorandum established a common direction: to improve collaboration, reduce obstacles that hinder development, and create a framework that supports health technologies reaching people more quickly and transparently.
Based on the MOU, the preparation of the 2025–2030 Innovation Roadmap and Action Plan was initiated. This document outlines the development of the sector comprehensively, from the initial idea to the adoption of solutions within the healthcare system.
At the official presentation of the roadmap on November 24, partner organizations had the opportunity to clarify their roles in this ecosystem and explain how they specifically support developers. The event provided a clear overview of how previously fragmented support structures and knowledge are being consolidated into a unified system that supports developers. The roadmap itself helps make the often uncertain development path predictable: development, validation, and market launch stages are defined, and for each stage, the involved parties providing support are described.
Estonian Business and Innovation Agency (EIS) previously highlighted that health technology development is typically one of the sectors with the longest development cycles. The central goal of the new roadmap is to shorten this cycle—not at the expense of quality, but through improved collaboration, early validation, testing opportunities, and regulatory clarity. Simplifying market entry, involving doctors and patients, and supporting the export of evidence-based solutions are part of the concrete actions outlined in the roadmap.
Metrosert’s Applied Research Center played a prominent role in the roadmap presentation. Janne Pullat, Head of the Health Data Division at the center, provided an overview of independent validation services that support developers in assessing the substantive performance and quality of technologies. Independent validation is crucial in health technology: before a developer can move on to regulatory processes or larger pilot projects, there must be evidence-based confirmation that the solution behaves as expected. Metrosert provides precisely this capability—a systematic assessment based on health data that helps make critical development decisions early and reduces technology-related risks.
For developers, this translates into practical support. Early validation creates a clearer development plan, allows resource savings, improves regulatory readiness, and facilitates communication with investors and healthcare partners. Metrosert’s role is thus part of a broader innovation ecosystem that helps raise development quality and increases the likelihood that new solutions reach users in an evidence-based and coordinated manner.
The roadmap also presents a longer-term perspective. The goal is to create an environment in Estonia where health technology development is supported at every stage: fostering knowledge-intensive startups, developing new research centers and testing capabilities, enabling effective and secure use of health data, and preparing the healthcare system for the implementation of new solutions. These activities support both the domestic market and international competitiveness.
In summary, the roadmap presentation demonstrates that a system for health technology development is taking shape in Estonia, where the vision agreed upon in the memorandum and the daily work of partners are aligned. The innovation roadmap provides a shared foundation, and Metrosert’s Applied Research Center adds a quality layer based on health data, supporting reliable and evidence-based solution development. This collaborative approach increases the likelihood that new health technologies will reach people in the future faster, through a clearer process, and with confidence for both developers and users.
See more: Innovation Roadmap and Action Plan.